Individual with over 35 years of experience in the pharmaceutical industry, large, mid-size and biotech (both publicly traded and private), in a broad range of roles spanning global Executive Leadership, R&D, Business Development, Strategic Marketing, and Commercial Operations, in a broad range of disease areas; creative entrepreneur and founder of two companies, one focused on late-stage development of ophthalmic medications; extensive knowledge of the pharmaceutical value chain, with a particular interest in the research and development through approval, launch and market positioning of products with a high degree of differentiation; responsible for critical strategies in the development of major blockbuster medications, including adalimumab (Humira®) and insulin glargine (Lantus®); highly versed in effective and efficient leadership of large, complex and global organizations, such as global R&D with more than 1700 associates, but also successful when leading and contributing to a small team in a biotech environment; highly analytical, strategic, but also results-oriented and energetic, with high standards. Dual citizen of Germany and the US.